Pioneering the science of time

Every day, we seek to transform science into more time for life. Time to be with families, time to be active community members, time to feel the small moments of joy that shape our lives.

Our company

Photo: K.G., living with systemic mastocytosis

The urgency of now

We are constantly on the move, relentless in our determination to accelerate development of new therapies, advance clinical trials and quickly bring approved medicines to patients worldwide.

Our pipeline

Photo: C.N., living with systemic mastocytosis

Targeting root causes of disease

We have a proven track record of developing medicines, and we aim to scale our impact by advancing innovative therapies for large patient populations with allergic/inflammatory diseases and cancer.

Our platform

Diversity sparks innovation

Our diverse team is passionate about science and thrives on working together to achieve the impossible. We use every opportunity to think differently, make bold decisions and pioneer novel solutions.

Our opportunities

Recent News

More News

Events and presentations

More events and presentations

Our commitment to patients

At Blueprint Medicines, we work together in pursuit of one common goal: to dramatically improve and extend patients’ lives.

read on

Core programs

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Avapritinib

Approved indications: U.S. and Europe

  • Adults with indolent systemic mastocytosis
  • Adults with advanced systemic mastocytosis
  • Adults with unresectable or metastatic gastrointestinal stromal tumor harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations
Learn more

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Elenestinib

development programs

  • Indolent systemic mastocytosis
  • Advanced systemic mastocytosis
Learn more

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

BLU-808

planned development programs

  • Chronic spontaneous and inducible urticaria
  • Additional common mast cell-mediated diseases
Learn more

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

BLU-222

Development programs

  • Hormone-receptor-positive, HER2-negative metastatic
    breast cancer
  • Other CDK2-vulnerable cancers, including ovarian and endometrial cancer
Learn more

Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc.

Meet the Blue Crew

Meet the Blue Crew

Brittany Carroll, Vice President, Therapy Area Lead

I lead a team tasked with guiding our long-term strategy for mast cell diseases. We work across all functions, from research to development to commercial, to map out strategic plans for our therapeutics and targets while ensuring that cross-functional teams are set up to best support the patients we serve.

Read on

We aspire to pioneer multiple new scientific advances in disease biology and the design of precision therapies. To learn more about our scientific leadership and perspectives, visit Our Blueprint.

read on

Targeting the core biology of disease

Our scientific presentations and publications

Seeking to deliver transformative medicines

Download Our latest corporate presentation
“We ignore traditional boundaries and let science drive us. It’s the only way to revolutionize how we treat cancer.”
Kate Haviland, Chief Executive Officer
“We ignore traditional boundaries and let science drive us. It’s the only way to revolutionize how we treat cancer.”
Kate Haviland, Chief Executive Officer

Dare to be different

We believe diversity is the key to unlocking our full potential. We push boundaries and take well-calculated risks, committing courageously and wholeheartedly to what we believe in.

read on